Page 23 - மீடியா வாழ்க்கைத்தொழில்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article SILVER SPRING, Md., April 13, 2021 /PRNewswire/ The following statement is attributed to Dr. Peter Marks, director of the FDA s Center for Biologics Evaluation and Research and Dr. Anne Schuchat, Principal Deputy Director of the CDC As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blo

Johnson janssenAnne schuchatPeter marksAdvisory committee on immunization practicesOffice of media affairsBiologics evaluationPrincipal deputy directorAdvisory committeeImmunization practicesVaccine adverse event reporting systemMedia affairsUs food and drug administrationஜான்சன் ஜான்சன்பீட்டர் மதிப்பெண்கள்அலுவலகம் ஆஃப் மீடியா வாழ்க்கைத்தொழில்கள்உயிரியல் மதிப்பீடு